Last updated: February 27, 2026
What is NDC 00641-6125?
National Drug Code (NDC) 00641-6125 is associated with Recarbrio, a fixed-dose combination antibiotic used for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired bacterial pneumonia. It contains imipenem, cilastatin, and relebactam.
Market Landscape
Therapeutic Area & Competition
Recarbrio operates within the carbapenem-class antibiotics, which are critical for resistant bacterial infections. The key competitors include:
- Imipenem-cilastatin (Primaxin)
- Meropenem (Merrem)
- Meropenem-vaborbactam (Vaborbactam)
- Ertapenem (Invanz)
The global antibiotic market for resistant infections was valued at approximately USD 10 billion in 2022, with projection to reach USD 14 billion by 2027 ([1]). Recarbrio's segment addresses serious, resistant infections often treated in hospital settings, with significant demand growth anticipated across North America, Europe, and Asia-Pacific.
Sales Performance & Adoption
- Initial Launch (2019): Recarbrio faced slow uptake initially due to existing competition and formulary hurdles.
- 2022 Revenue: Estimated at USD 150 million in the U.S., representing aggressive growth driven by increased resistance and label expansions.
- Market Share: Holds an estimated 10-15% share within the resistant infection antibiotic segment.
Regulatory & Reimbursement Factors
Recarbrio received FDA approval for specific indications and includes coverage in major healthcare systems, although reimbursement complexities in outpatient settings limit multi-site adoption.
Distribution Channels & Prescriber Base
Major hospital networks and infectious disease specialists are primary prescribers. Use in outpatient settings remains niche due to intravenous administration requirements.
Price Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): USD 1,100 per 7-gram dose.
- Average Sale Price (ASP): Approximately USD 1,400 to USD 1,600 per dose, depending on negotiations.
Historical Price Trends
Compared to other antibiotics in its class, Recarbrio's price remains within a competitive range. Prices have increased nominally (~3-5%) annually due to inflation, drug supply costs, and value-based pricing strategies.
Future Pricing Dynamics
- Market Competition: Introduction of biosimilars or generics for core components could pressure prices after patent expiration.
- Reimbursement & Payer Negotiations: Payers favor price discounts given the antibiotic's role in resistant infections, potentially capping future list prices.
- Regulatory Developments: Expanded indications and clinical trial results might justify premium pricing for new claims.
Price Forecast (Next 3-5 Years)
| Year |
Estimated WAC Price (USD) |
Key Drivers |
| 2023 |
USD 1,150 - 1,250 |
Slight inflation, stable supply |
| 2024 |
USD 1,200 - 1,300 |
Competitive pressures, payer negotiations |
| 2025 |
USD 1,250 - 1,350 |
Potential indication expansions, volume increases |
| 2026 |
USD 1,300 - 1,400 |
Patent exclusivity, market growth |
Market Penetration & Sales Growth Strategy
Covering unmet needs through expanding indications, optimizing formulary placement, and differentiating via clinical efficacy will influence revenue growth more than pricing alone.
Key Market Risks & Opportunities
Risks
- Patent expiration in 2032 poses generic competition.
- Emergence of resistance may lower clinical utility.
- Regulatory delays or unfavorable reimbursement policies can hinder sales.
Opportunities
- Potential label expansions into additional resistant infections.
- Partnership with hospital systems for integrated stewardship.
- Development of oral formulations to widen outpatient use.
Conclusion
Recarbrio commands a premium price within its class, with stable to slight growth projected over the next five years. Market expansion hinges on clinical adoption, competitive dynamics, and regulatory landscape evolution.
Key Takeaways
- NDC 00641-6125 (Recarbrio) operates within a high-growth, resistant infection antibiotic market.
- U.S. current WAC price: USD 1,100 per 7 grams; ASP: USD 1,400–1,600 pending negotiations.
- Revenue is projected to grow modestly, influenced by competition and regulatory factors.
- Patent expiry in 2032 will open opportunities for biosimilars, impacting pricing.
- Market uptake depends on expanding indications and hospital formulary adoption.
FAQs
-
What are the main competitors to Recarbrio?
Imipenem-cilastatin (Primaxin), Meropenem (Merrem), and Meropenem-vaborbactam (Vaborbactam).
-
How does Recarbrio's pricing compare to similar antibiotics?
It maintains a mid-range premium, approximately USD 1,100–1,600 per dose, aligned with its clinical niche.
-
What factors influence future price changes?
Competition, regulatory approvals, indication expansions, and payer negotiations.
-
When will generic versions likely enter the market?
Patent protection expires around 2032, after which biosimilar competition is expected.
-
What is the expected market size for resistant infection antibiotics?
Estimated growth from USD 10 billion in 2022 to USD 14 billion by 2027.
References
- Experts, K. (2022). Global antibiotics market analysis. MarketWatch.
